A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia.

Br J Haematol 2014 Dec 21;167(5):618-25. Epub 2014 Aug 21.

Department of Haematology, Westmead Hospital, Sydney, NSW, Australia.

Gastrointestinal toxicity, including oral mucositis, is a frequent complication of intensive combination chemotherapy for acute myeloid leukaemia (AML) and contributes substantially to treatment-related mortality. We conducted a placebo-controlled randomized trial to evaluate the efficacy of palifermin (keratinocyte growth factor), given at 60 μg/kg per daily IV for 3 d before and after chemotherapy, for mucosal protection in adult patients with previously untreated AML receiving induction therapy with idarubicin, high-dose cytarabine and etoposide. Among 155 randomized patients, there was no statistically significant difference in the rate of grade 3 and 4 oral mucositis (primary study endpoint) between the two treatment arms (three in palifermin arm (4%), 8 in placebo arm (10%; P = 0·21); however, when considering the severity of oral mucositis (World Health Organization grade 0-4), there was evidence of reduced rates of higher grades of oral mucositis in the palifermin arm (P = 0·0007, test for trend). There was a statistically significantly lower rate of grades 3 and 4 gastrointestinal adverse events in the palifermin arm (21% vs. 44% in placebo arm; P = 0·003), mainly due to a reduction in severe diarrhoea (8% palifermin, 26% placebo; P = 0·01). Palifermin has activity as a mucosal protectant in AML patients receiving intensive chemotherapy. This trial is registered at ACTRN012605000095662.

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13086DOI Listing
December 2014
47 Reads

Publication Analysis

Top Keywords

oral mucositis
16
palifermin arm
12
gastrointestinal toxicity
8
placebo arm
8
induction therapy
8
acute myeloid
8
randomized trial
8
myeloid leukaemia
8
palifermin
7
arm
5
therapy idarubicin
4
receiving induction
4
trend statistically
4
test trend
4
p = 0·0007 test
4
mucositis palifermin
4
etoposide 155
4
155 randomized
4
cytarabine etoposide
4
arm p = 0·0007
4

Similar Publications